These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1180547)

  • 1. Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice.
    Hackman AS; Wilkins TD
    Antimicrob Agents Chemother; 1975 Aug; 8(2):224-5. PubMed ID: 1180547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of cephalothin and cefoxitin into experimental infections with Bacteroides fragilis.
    O'Keefe JP; Tally FP; Barza M; Gorbach SL
    Rev Infect Dis; 1979; 1(1):106-12. PubMed ID: 318211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
    Bergeron MG; Gauvreau L; Nguyen BM
    Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro susceptibility of bacteroidaceae to cefoxitin and cephalothin (author's transl)].
    Werner H; Firsching R; Krasemann C
    Infection; 1977; 5(1):13-6. PubMed ID: 856727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-lactamases in bacteroides.
    Nord CE; Olsson B; Dornbusch K
    Scand J Infect Dis Suppl; 1978; (13):27-32. PubMed ID: 28561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis.
    Hackman AS; Wilkins TD
    Antimicrob Agents Chemother; 1975 May; 7(5):698-703. PubMed ID: 1041218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
    Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
    Beale AS; Gisby J
    Infection; 1991; 19(2):101-5. PubMed ID: 2050417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intravenous cefoxitin sodium in patients with obstetric/gynaecologic infections.
    White JS; Gee C; Ledger WJ
    J Antimicrob Chemother; 1978 Jul; 4(B):239-40. PubMed ID: 357395
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies with cefuroxime and cefoxitin.
    Geddes AM; McGhie D; Ball AP; Gould I
    Scand J Infect Dis Suppl; 1978; (13):78-81. PubMed ID: 308260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of cephalosporins by Bacteroides.
    Tally FP; O'Keefe JP; Sullivan NM; Gorbach SL
    Antimicrob Agents Chemother; 1979 Nov; 16(5):565-71. PubMed ID: 525995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synergistic effect of thiamphenicol and cephalothin on Bacterioides fragilis (author's transl)].
    Isono M; Aoki M; Kobayashi T; Marui T; Yamada H; Umemura A; Watanabe K; Ueno K
    Jpn J Antibiot; 1981 May; 34(5):647-50. PubMed ID: 7026821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
    Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
    Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of an experimental Bacteroides fragilis infection in mice.
    Walker CB; Nitzan D; Wilkins TD
    Antimicrob Agents Chemother; 1977 Mar; 11(3):435-40. PubMed ID: 855998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects on antibacterial treatment of anaerobic infections.
    Nordbring F; Nord CE
    Scand J Infect Dis Suppl; 1982; 35():59-62. PubMed ID: 6762654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.
    Brook I
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1531-5. PubMed ID: 8363386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for experimental intraabdominal sepsis: comparison of four cephalosporins with clindamycin plus gentamicin.
    Louie TJ; Onderdonk AB; Gorbach SL; Bartlett JG
    J Infect Dis; 1977 Mar; 135 Suppl():S18-22. PubMed ID: 321707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
    Malouin F; Lamothe F
    Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.